Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP1 | P53582 | 5/20 | 0.45 |
| ▸ | ACHE | P22303 | 2/20 | 0.38 |
| ▸ | MIF | P14174 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16153706 | 0.85 | METAP1 (0.57) | METAP1ACHEGAAKMT2A | |
| SCHEMBL18322173 | 0.83 | MIF (0.35) | METAP1MIFGAAKMT2A | |
| SCHEMBL20241204 | 0.83 | MIF (0.35) | METAP1MIFGAAKMT2A | |
| SCHEMBL20241203 | 0.83 | MIF (0.35) | METAP1MIFGAAKMT2A | |
| SCHEMBL6067801 | 0.83 | METAP1 (0.46) | METAP1ACHE | |
| SCHEMBL15016447 | 0.83 | METAP1 (0.42) | METAP1ACHE | |
| SCHEMBL18322114 | 0.82 | METAP1 (0.45) | METAP1ACHE | |
| SCHEMBL18321932 | 0.80 | GLA (0.43) | METAP1ACHEKMT2A | |
| SCHEMBL9938389 | 0.80 | METAP1 (0.55) | METAP1ACHE | |
| SCHEMBL31374607 | 0.80 | METAP1 (0.55) | METAP1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3766878-B1 | NRF2 REGULATORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2022-03-16 | — | — | EP | disclosed |
| CN-108137557-B | Nrf2 modulators | 葛兰素史密斯克莱知识产权发展有限公司 | 2021-09-07 | — | — | CN | disclosed |
| EP-3766878-A1 | NRF2 REGULATORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2021-01-20 | — | — | EP | disclosed |
| EP-3307729-B1 | NRF2 REGULATORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-09-02 | — | — | EP | disclosed |
| US-20190224212-A1 | Nrf2 REGULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2019-07-25 | — | — | US | disclosed |
| US-20190224212-A1 | Nrf2 REGULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2019-07-25 | — | — | US | disclosed |
| US-10272095-B2 | NRF2 regulators | GlaxoSmithKline Intellectual Propert Development Limited (GB) | 2019-04-30 | — | — | US | disclosed |
| US-10272095-B2 | NRF2 regulators | GlaxoSmithKline Intellectual Propert Development Limited (GB) | 2019-04-30 | — | — | US | disclosed |
| EP-3126346-B1 | SUBSTITUTED INDANONE COMPOUNDS AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS | SANOFI SA (FR) | 2018-07-11 | — | — | EP | disclosed |
| US-20180169110-A1 | Nrf2 REGULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2018-06-21 | — | — | US | disclosed |
| WO-2018104766-A1 | 3-(2,3-DIHYDRO-1H-INDEN-5-YL)PROPANOIC ACID DERIVATIVES AND THEIR USE AS NRF2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-06-14 | — | — | WO | disclosed |
| EP-3307729-A1 | NRF2 REGULATORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2018-04-18 | — | — | EP | disclosed |
| US-9896434-B2 | Substituted indanone compounds as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders | SANOFI (FR) | 2018-02-20 | — | — | US | disclosed |
| EP-3126346-A1 | SUBSTITUTED INDANONE COMPOUNDS AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS | SANOFI (FR) | 2017-02-08 | — | — | EP | disclosed |
| US-20170029405-A1 | SUBSTITUTED INDANONE COMPOUNDS AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS | SANOFI (FR) | 2017-02-02 | — | — | US | disclosed |
| WO-2016203401-A1 | NRF2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-12-22 | — | — | WO | disclosed |
| WO-2015150563-A1 | SUBSTITUTED INDANONE COMPOUNDS AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS | SANOFI (FR) | 2015-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10272095-B2 | NRF2 regulators | NFE2L2, KEAP1, NQO1 | METAP1 3473/4885ACHE 4744/4885MIF 1906/4885 |
| US-20190224212-A1 | Nrf2 REGULATORS | NFE2L2, KEAP1, NQO1 | METAP1 3473/4885ACHE 4744/4885MIF 1906/4885 |
| US-20180169110-A1 | Nrf2 REGULATORS | NFE2L2, KEAP1, NQO1 | METAP1 3473/4885ACHE 4744/4885MIF 1906/4885 |
| US-20170029405-A1 | SUBSTITUTED INDANONE COMPOUNDS AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS | GPR119, INSR, GPR65 | METAP1 2762/4885ACHE 3862/4885MIF 2253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.